Squarepoint
PRAX icon

Squarepoint’s Praxis Precision Medicines PRAX Stock Holding History

Squarepoint’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Buy
2,010
+120
+6% +$37.1K ﹤0.01% 3125
2025
Q4 		$557K Buy
+1,890
New +$352K ﹤0.01% 3122
2025
Q1 		– Sell
-7,782
Closed -$599K – 5228
2024
Q4 		$599K Sell
7,782
-6,876
-47% -$498K ﹤0.01% 3578
2024
Q3 		$843K Buy
14,658
+1,310
+10% +$70.8K ﹤0.01% 2728
2024
Q2 		$552K Buy
13,348
+6,942
+108% +$328K ﹤0.01% 3003
2024
Q1 		$391K Buy
+6,406
New +$287K ﹤0.01% 3215
2023
Q2 		– Sell
-3,102
Closed -$37.6K – 3909
2023
Q1 		$37.6K Buy
3,102
+1,394
+82% +$58.8K ﹤0.01% 3080
2022
Q4 		$61K Sell
1,708
-10,106
-86% -$315K ﹤0.01% 3033
2022
Q3 		$402K Buy
11,814
+10,377
+722% +$517K ﹤0.01% 2312
2022
Q2 		$53K Buy
+1,437
New +$153K ﹤0.01% 2701
2021
Q3 		– Sell
-1,162
Closed -$319K – 3322
2021
Q2 		$319K Buy
+1,162
New +$416K ﹤0.01% 2481

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Squarepoint's PRAX Position: Q1 2026 in Review

Squarepoint increased its Praxis Precision Medicines (PRAX) stake by 6.3% in Q1 2026, buying an estimated $37.1K and bringing the position to 2,010 shares worth $648K. The position accounts for ﹤0.01% of the portfolio, ranked #3125.

Squarepoint first reported a position in PRAX in Q2 2021 and has held it in 11 quarters since. The position peaked at $843K in Q3 2024. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Squarepoint held 2,010 shares of Praxis Precision Medicines worth $648K as of Q1 2026.
  • Squarepoint bought 120 Praxis Precision Medicines shares in Q1 2026, an estimated $37.1K.
  • Praxis Precision Medicines made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3125 holding.
  • Squarepoint first reported a position in Praxis Precision Medicines in Q2 2021 and has held it in 11 quarters since.
  • Squarepoint's Praxis Precision Medicines position peaked at $843K in Q3 2024.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.